Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,115,800 | 2,444,400 | 1,198,500 | 895,500 | 636,056 |
| Depreciation Amortization | 210,300 | 148,200 | 145,500 | 104,700 | 74,909 |
| Income taxes - deferred | -130,600 | -140,000 | 318,800 | -360,100 | -121,623 |
| Accounts receivable | -523,700 | -236,400 | -362,700 | -143,800 | -491,421 |
| Other Working Capital | -200,500 | -697,000 | -926,500 | 240,800 | 229,827 |
| Other Operating Activity | 958,700 | 675,900 | 933,500 | 748,800 | 1,003,032 |
| Operating Cash Flow | $2,430,000 | $2,195,100 | $1,307,100 | $1,485,900 | $1,330,780 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -1,598,200 | -1,069,900 | -732,600 | -534,900 | -229,668 |
| PPE Investments | -429,600 | -383,100 | -272,600 | -511,900 | -677,933 |
| Other Investing Activity | 0 | -10,000 | 0 | 0 | 0 |
| Investing Cash Flow | $-2,027,800 | $-1,463,000 | $-1,005,200 | $-1,046,800 | $-907,601 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 0 | 0 | 57,000 | 5,100 | 27,373 |
| Debt Repayment | N/A | N/A | -19,900 | -45,700 | -741,307 |
| Common Stock Issued | 211,800 | 114,500 | 240,200 | -516,700 | 206,358 |
| Common Stock Repurchased | -463,900 | -191,600 | -301,700 | -143,200 | -160,537 |
| Other Financing Activity | 0 | 0 | 0 | 0 | 405,317 |
| Financing Cash Flow | $-252,100 | $-77,100 | $-24,400 | $-700,500 | $-262,796 |
| Beginning Cash Position | 1,480,200 | 825,200 | 547,700 | 809,100 | 648,719 |
| End Cash Position | 1,630,300 | 1,480,200 | 825,200 | 547,700 | 809,102 |
| Net Cash Flow | $150,100 | $655,000 | $277,500 | $-261,400 | $160,383 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,430,000 | 2,195,100 | 1,307,100 | 1,485,900 | 1,330,780 |
| Capital Expenditure | -429,600 | -383,100 | -272,600 | -511,900 | -677,933 |
| Free Cash Flow | 2,000,400 | 1,812,000 | 1,034,500 | 974,000 | 652,847 |